Entity
  • SolasCure

    Created in 2017
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    1,447
  • Activities

  • Technologies

  • Entity types

  • Location

    wellington house, East Rd, Petersfield, Cambridge CB1 1BH, UK

    Cambridge

    United Kingdom

  • Employees

    Scale: 2-10

    Estimated: 17

  • Engaged corporates

    2
    1 1
  • Added in Motherbase

    1 year, 10 months ago
Description
  • Value proposition

    Transforming chronic wound care with a breakthrough wound therapeutic

    Chronic wounds affect ~100m people around the world, impacting quality of life & placing a huge burden on health systems. Despite the many innovations in wound care over the years, chronic wound healing rates have barely improved. Change is needed – patients, practitioners, and regulators across the industry are in urgent need of high-impact innovations in chronic wound care.

    SolasCure is at the forefront of addressing this demand, aiming to shift the current treatment
    paradigm with a high impact therapeutic approach to debridement, with the goal of enabling dramatic improvements in healing rates and patients’ quality of life.

    Aurase Wound Gel aims to address the huge unmet need for easy & effective debridement to return wounds to healing. It combines the enzyme Tarumase with hydrogel to debride wounds, reduce biofilm & promote healing. Tarumase is a highly-specific fibrinolytic enzyme cloned from maggot saliva, perfectly optimised by evolution for wound bed preparation.

    After successful Phase IIa trials, SolasCure is preparing for the next phase of clinical development to bring Aurase Wound Gel one step closer to improving the lives of millions of patients suffering from chronic wounds.

    For more information, you can find our peer-reviewed publications here:
    Clinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14805
    Preclinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14079


    The importance of our innovative technology has been widely recognised:
    - Innovate UK Global Incubator Programme (Innovate UK, the UK’s Innovation Agency), Texas Medical Center, 2024
    - Biomedical Catalyst Grant (Innovate UK, the UK’s Innovation Agency), 2024
    - EIC Accelerator Grant (European Innovation Council), 2023
    - Life Sciences Innovator (UK Department for Trade and Business), 2023
    - EIT Health Catapult, Biotech Category (European Institute of Innovation & Technology), 2022
    - Winner 2019 URGO Mentorship Programme.

    Visit us at www.solascure.com

    wound therapy, enzymes, and biopharma

Corporate interactions BETA
Corporate TypeTweets Articles
UK Atomic Energy Authority
UK Atomic Energy Authority
Research, National and local authorities
UK Atomic Energy Authority
Research, National and local authorities
Other

31 Aug 2024


Pharma IQ
Pharma IQ
Pharmaceutical, Pharmaceutical Manufacturing
Pharma IQ
Pharmaceutical, Pharmaceutical Manufacturing
Other

17 Nov 2022


Similar entities
Loading...
Loading...
Social network dynamics